Literature DB >> 26045979

TGF-β signaling and its targeting for glioma treatment.

Jianfeng Han1, Christopher A Alvarez-Breckenridge2, Qi-En Wang3, Jianhua Yu1.   

Abstract

Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine, secreted by a variety of cells including immune cells, tumor cells, and stromal cells. TGF-β signaling is dysregulated in cancer patients, and this aberrant signaling at least in part contributes to initiation and progression of many cancers including glioma. The dysregulated signaling components provide molecular targets for the treatment of glioma. In this article, we review TGF-β signaling and its targeting in glioma.

Entities:  

Keywords:  TGF-β; TGF-β signaling; glioma; glioma treatment; gliomagenesis

Year:  2015        PMID： 26045979      PMCID： PMC4449428     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


  77 in total

1.  Increased migration of a human glioma cell line after in vitro CyberKnife irradiation.

Authors:  Alessandra Canazza; Chiara Calatozzolo; Luisa Fumagalli; Achille Bergantin; Francesco Ghielmetti; Laura Fariselli; Danilo Croci; Andrea Salmaggi; Emilio Ciusani
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

Review 2.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

3.  Transforming growth factor beta and cell cycle regulation.

Authors:  M G Alexandrow; H L Moses
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

4.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

Review 5.  Exploring anti-TGF-β therapies in cancer and fibrosis.

Authors:  Lukas J A C Hawinkels; Peter Ten Dijke
Journal:  Growth Factors       Date:  2011-06-30       Impact factor: 2.511

6.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

Authors:  Courtney A Crane; Seunggu J Han; Jeffery J Barry; Brian J Ahn; Lewis L Lanier; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2009-11-05       Impact factor: 12.300

7.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

Review 8.  Role of TGF-beta in immune-evasion of cancer.

Authors:  C Beck; H Schreiber; D Rowley
Journal:  Microsc Res Tech       Date:  2001-02-15       Impact factor: 2.769

9.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

10.  Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.

Authors:  Emilia Fransvea; Umberto Angelotti; Salvatore Antonaci; Gianluigi Giannelli
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425
View more
  88 in total

1.  Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.

Authors:  Kelli A Lytle; Christopher M Depner; Carmen P Wong; Donald B Jump
Journal:  J Lipid Res       Date:  2015-08-27       Impact factor: 5.922

2.  ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.

Authors:  Kang Song; Ye Yuan; Yong Lin; Yan-Xia Wang; Jie Zhou; Qu-Jing Gai; Lin Zhang; Min Mao; Xiao-Xue Yao; Yan Qin; Hui-Min Lu; Xiang Zhang; You-Hong Cui; Xiu-Wu Bian; Xia Zhang; Yan Wang
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

3.  Clonal evolution of glioblastoma under therapy.

Authors:  Jiguang Wang; Emanuela Cazzato; Erik Ladewig; Veronique Frattini; Daniel I S Rosenbloom; Sakellarios Zairis; Francesco Abate; Zhaoqi Liu; Oliver Elliott; Yong-Jae Shin; Jin-Ku Lee; In-Hee Lee; Woong-Yang Park; Marica Eoli; Andrew J Blumberg; Anna Lasorella; Do-Hyun Nam; Gaetano Finocchiaro; Antonio Iavarone; Raul Rabadan
Journal:  Nat Genet       Date:  2016-06-06       Impact factor: 38.330

4.  Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.

Authors:  Friedrich Erhart; Matthias Hackl; Hannes Hahne; Johanna Buchroithner; Chen Meng; Simone Klingenbrunner; René Reitermaier; Katrin Fischhuber; Susanna Skalicky; Walter Berger; Sabine Spiegl-Kreinecker; Daniela Lötsch; Gerda Ricken; Bernhard Kuster; Adelheid Wöhrer; Georg Widhalm; Johannes Hainfellner; Thomas Felzmann; Alexander M Dohnal; Christine Marosi; Carmen Visus
Journal:  NPJ Vaccines       Date:  2020-01-16       Impact factor: 7.344

5.  Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.

Authors:  Jorrit De Waele; Elly Marcq; Jonas Rm Van Audenaerde; Jinthe Van Loenhout; Christophe Deben; Karen Zwaenepoel; Erik Van de Kelft; David Van der Planken; Tomas Menovsky; Johan Mj Van den Bergh; Yannick Willemen; Patrick Pauwels; Zwi N Berneman; Filip Lardon; Marc Peeters; An Wouters; Evelien Lj Smits
Journal:  Oncoimmunology       Date:  2017-12-12       Impact factor: 8.110

Review 6.  Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Authors:  Russell Maxwell; Christopher M Jackson; Michael Lim
Journal:  Curr Treat Options Oncol       Date:  2017-08

7.  LPS induces HUVEC angiogenesis in vitro through miR-146a-mediated TGF-β1 inhibition.

Authors:  Yize Li; Huayu Zhu; Xu Wei; Heng Li; Zhicao Yu; Hongmei Zhang; Wenchao Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

8.  Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth.

Authors:  Jiping Wang; Jianmei W Leavenworth; Anita B Hjelmeland; Reed Smith; Neha Patel; Ben Borg; Ying Si; Peter H King
Journal:  Glia       Date:  2019-08-10       Impact factor: 7.452

Review 9.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

10.  miR-373 Inhibits Glioma Cell U251 Migration and Invasion by Down-Regulating CD44 and TGFBR2.

Authors:  Furong Wei; Qianrong Wang; Qinghong Su; Haiyan Huang; Junwen Luan; Xiaoqun Xu; Junfu Wang
Journal:  Cell Mol Neurobiol       Date:  2016-02-08       Impact factor: 5.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.